Renal transplant recipients need life long immunosuppression and one of the new drugs is everolimus. Everolimus is a potent immunosuppressive drug and one of the main side-effects are increased blood cholesterol levels. Many renal transplant recipients are treated with a cholesterol lowering agent, mainly fluvastatin. Rosuvastatin is a new cholesterol lowering drug on the market with a potential higher cholesterol lowering potency. In the present study the investigators will examine the hypothesis that rosuvastatin reduce cholesterol levels more than fluvastatin in renal transplant patients.

Inclusion Criteria:

• Renal transplant recipients with stable renal function (plasma creatinine < 200 µmol/L)
• Renal transplant recipients on an everolimus and fluvastatin based therapy for minimum 3 months prior to inclusion
• > 18 years of age
• Male patient or female patient without childbearing potential (surgically sterilized or postmenopausal) or if female of childbearing potential; is not lactating, has a negative pregnancy test at screening and is willing to utilize an effective method of contraception throughout the study period and for 90 days following discontinuation of the study drugs
• Signed informed consent

Exclusion Criteria:

• Patients experiencing an acute rejection episode within 2 weeks before or after inclusion, whether proven by biopsy or not
• Patients with a known hypersensitivity to rosuvastatin
• Change in enzyme inducing or inhibiting drugs within the last 2 weeks prior to and throughout the study [e.g. barbiturates, rifampicin, ketoconazole, erythromycin, cimetidine and similar drugs]
• Pregnant or nursing mothers